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Premotor compensationThe delayed appearance ofmotor symptoms in PD poses a crucial challenge for early detection of the disease.We
measured the binding potential of the selective dopamine active transporter (DAT) radiotracer [11C]PE2I in
MPTP-treated macaque monkeys, thus establishing a detailed proﬁle of the nigrostriatal DA status following
MPTP intoxication and its relation to induced motor and non-motor symptoms. Clinical score and cognitive per-
formancewere followed throughout the study.Wemeasured longitudinally in vivo the non-displaceable binding
potential to DAT in premotor, motor-recovered (i.e. both non-symptomatic) and symptomatic MPTP-treated
monkeys.
Results show an unexpected and pronounced dissociation between clinical scores and [11C]PE2I-BPND during the
premotor phase i.e. DAT binding in the striatumof premotor animalswas increased around 20%. Importantly, this
broad increase of DAT binding in the caudate, ventral striatum and anterior putamen was accompanied by
i) deteriorated cognitive performance, showing a likely causal role of the observed hyperdopaminergic state
(Cools, 2011; Cools and D'Esposito, 2011) and ii) an asymmetric decrease of DAT binding at a focal point of the
posterior putamen, suggesting that increased DAT is one of the earliest, intrinsic compensatorymechanisms. Fol-
lowing spontaneous recovery from motor deﬁcits, DAT binding was greatly reduced as recently shown in-vivo
with other radiotracers (Blesa et al., 2010, 2012). Finally, high clinical scores were correlated to considerably
low levels of DAT only after the induction of a stable parkinsonian state. We additionally show that the only
striatal region which was signiﬁcantly correlated to the degree of motor impairments is the ventral striatum.
Further research on this period should allow better understanding of DA compensation at premature stages of PD
and potentially identify new diagnosis and therapeutic index.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Parkinson's disease (PD) is a neurodegenerative pathology charac-
terized by the progressive death of the dopamine (DA) neurons of the
substantia nigra pars compacta (SNpc) that innervate the caudate
nucleus and putamen. Chronic treatment with MPTP, a speciﬁc toxinbeta-carbomethoxy-3beta-(4′-
P, 1-methyl-4-phenyl-1,2,3,6-
mography; NHP, non-human
ute (ESI) for Neuroscience in
, Germany. Fax: +49 69 96769
i).
re d'Imagerie et Neurosciences
. This is an open access article underof DA cells, produces symptoms similar to those observed in PD patients
and provides a useful model of PD.
In both human and NHP DA cell loss has to exceed 30% and the DA
markers in the caudate/putamen to drop by 60–70% before PD motor
symptoms are observed (Agid, 1991; Burke and O'Malley, 2013;
Tabbal et al., 2012), suggesting the existence of compensatory and
adaptive processes. An improved understanding of this premotor PDpe-
riod will contribute to clinical advances in the diagnosis, and treatment
of PD.
In non-human primates, the chronic low dose MPTP-treatment
causes a tempo of DA cell loss and a repertoire of motor symptoms sim-
ilar to those observed in PD (Bezard et al., 1997a, 1997b; Schneider and
Pope-Coleman, 1995), therebyproviding a valuablemodel for the inves-
tigation of the phase preceding the appearance of characteristic motor
symptoms. Interruption of MPTP intoxication produces a stabilization
of motor symptoms and in some cases, is followed by spontaneousthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
250 J. Vezoli et al. / NeuroImage 102 (2014) 249–261motor recovery (Boulet et al., 2008; Petzinger et al., 2006; Vezoli et al.,
2011). In humans, even a short lasting exposure to MPTP can cause a
progressive and ultimately fatal pathology in the SN (Vingerhoets
et al., 1994). The progression of clinical symptoms correlates well with
levels of nigrostriatal DA depletion in both PD patients (Burke and
O'Malley, 2013; Hornykiewicz, 2006, 2008) and MPTP-treated NHP
(Blesa et al., 2010). However, DA lesion can be severe in motor-
recovered animals following exposure to MPTP (Boulet et al., 2008) as
well as in motor-asymptomatic animals (Bezard et al., 2001; Schneider,
1990); suggesting that the compensatory process is not uniquely DA de-
pendent (Bezard et al., 2003;Mounayar et al., 2007). Hence, understand-
ing the evolution of DAmetabolic alterations during the premotor phase
of the pathology will give an improved insight into the compensatory
process (Tang et al., 2010). Given the absence of a reliable marker of
the premotor PD phase in humans, investigation of animal models re-
mains crucial (Berg et al., 2013; Siderowf and Lang, 2012).
In view of the above we have studied the DA status of the
nigrostriatal pathway in-vivo using Positron Emission Tomography
(PET), amethod of choice to quantify in-vivo neurodegeneration in lon-
gitudinal studies (Brown et al., 2013; Masilamoni et al., 2010). We used
the cocaine analog [11C]PE2I labeled with carbon 11, a ligand displaying
a selective afﬁnity for the DA transporter (DAT) thereby allowing pre-
cise measurement of its density (Poyot et al., 2001). Imaging studies in
both PD patients and MPTP-monkeys show a drop in DAT markers in
SN and striatum that correlates with the severity of disease (Brown
et al., 2013; Kugaya et al., 2000), and with DA neuron loss in SN and
nigrostriatal depletion (Brown et al., 2013; Niznik et al., 1991). Addi-
tionally, DAT label in de novo patients has been shown to predict
long-term motor and non-motor outcomes (Ravina et al., 2012). How-
ever few studies if any have directly addressed the premotor PD state
in humans.
In order to analyze the functional link between the onset of clinical
motor and non-motor symptoms (here cognitive) and levels of
nigrostriatal DA cell damage, we carried out longitudinal PET analysis
of the [11C]PE2I non-displaceable binding potentials ([11C]PE2I-BPND)
inmonkeys submitted to low-doseMPTP-treatment. Clinical symptoms
were assessed by extensive daily clinical scoring and task performance
was evaluated using a behavioral test relying on the integrity andDA in-
nervation of the fronto–striatal axis (Decamp and Schneider, 2004;
Schneider and Kovelowski, 1990).
Methods
Ethical statement
All procedures were carried out according to the 1986 European
Community Council Directives (86/609/EEC) which was the ofﬁcial di-
rective at the time of experiments, the French Commission for animal ex-
perimentation, the Department of Veterinary Services (DDSV Lyon,
France). Authorization for the present studywas delivered by the “Préfet
de la Région Rhône Alpes” and the “Directeur départemental de la pro-
tection des populations” under Permit Number: #A690290402. All pro-
cedures were designed with reference to the recommendations of the
Weatherall report, “The use of non-human primates in research”. All
monkeys were closely monitored on a regular basis throughout the
day, by researchers and animal care staff, in order to ensure that levels
of health and welfare were strictly maintained, particularly during the
MPTP period. Adaptations to housing and feeding procedures were
made in direct response to individual symptoms in the MPTP phase, for
example adaptations of water provision to ensure monkeys were able
to drink ad libitum. To alleviate physical suffering frommotor symptoms
progression (such as rigidity) the intoxication procedure was ﬁrst cau-
tiously stoppedwhen the PMRS-motor score was above ten for two con-
secutive days following oneMPTP injection; further, antalgic and/or anti-
inﬂammatory drugs were delivered to animals suffering from advanced
motor symptoms progression. Before being sacriﬁced, animals wereﬁrst tranquilized with a preanesthetic agent (chlorpromazine hydro-
chloride, Largactil) and anesthesia was induced with Ketamine before
deep anesthesia was obtained by means of a large dose of pentobarbital
sodium (Vibrac, 100 mg kg−1, i.p.; lethal dose conﬁrmed by complete
loss of corneal reﬂex).
Animals and MPTP intoxication
Four late middle-aged (11–13 years old) female macaque monkeys
(Macaca fascicularis [4-5 kg weight]) were intoxicated with low-dose
MPTP injections (0.2 mg kg−1, i.m). Animals were housed in a room
dedicated to MPTP experiments, with free access to water and received
food twice a day. The neurotoxin was delivered according to two differ-
ent regimes: 1) chronically each 3–4 days and 2) acute intoxication
(daily injections) as described previously (Mounayar et al., 2007;
Vezoli et al., 2011). In cases 1 and 3, the ﬁrst session of MPTP injections
was suspended as soon as the clinical score reached symptomatic thresh-
old (Fig. 1 and Supplementary Table 1), allowing investigation of DA
neurotransmission after spontaneous behavioral recovery (Vezoli et al.,
2011). For the last-MPTP intoxication which led to persistent motor-
symptoms in all cases, injections were cautiously stopped when the
PMRS-motor score was above ten for two consecutive days following a
single MPTP injection. For result presentation, animals were grouped ac-
cording to their clinical state at the time of PET-scan (see Fig. 1 and Sup-
plementary Tables 2–4) i.e. 1—premotor (n = 4, cases 1–4); 2—
spontaneously recovered (n=2, cases 1 and 3); and 3—stable symptom-
atic (n=4, cases 1–4). Data are presented according to the correspond-
ing periods of the MPTP-intoxication protocol: 1—early_MPTP
(second week of MPTP intoxication, premotor i.e. motor-asymptomatic,
within the pre-symptomatic period when clinical motor score below
5); 2—post-MPTP Recovery (following arrest of ﬁrst MPTP injections,
clinical motor score returned below 5 throughout this period i.e. non-
symptomatic); and 3—post-MPTP Symptomatic (following arrest of last
MPTP injections, clinical motor score remained stably above 5 during
this period i.e. motor-symptomatic).
Case 4 had a high-score two weeks post-MPTP (motor symptoms
N15), characterized by severe rigidity. Musculoskeletal pain is a recog-
nized source of pain syndromes and discomfort in Parkinson's disease
patients. We thus delivered regularly ketoprofen (Profenid), from
week 5 post-MPTP, in order to relieve suspected musculoskeletal pain.
Subsequently the clinical score for this animal progressively improved,
due to amelioration on the rigidity scale and ability to manipulate
food (from week 5 to week 10 post-MPTP, Fig. 1B), but stabilized at
week 10 and remained largely symptomatic (score N12) despite contin-
uous treatment and disappearance of apparent musculoskeletal pain
syndrome. No analgesics or anti-inﬂammatory drugs were delivered
to premotor or recovered animals.
Clinical motor evaluation
Clinical scoring was done by three experimenters at separate times
throughout the day, 3–5 days per week using the ParkinsonianMonkey
Rating Scale (Vezoli et al., 2011). The PMRS contains a motor compo-
nent, employing a previously published scale (Benazzouz et al., 1995)
used to deﬁne the onset of the motor symptomatic period. The total
score for freezing (0–3), resting tremor (0–3, for right and left side), ri-
gidity (0–3), posture (0–2), bradykinesia (0–3), and ability to manipu-
late food (0–3, for right and left side) was used to frame injections
(maximum total score of 23): a score below 5 deﬁned the non-
symptomatic state in premotor and recovery periods, and a score
above 5 deﬁned symptomatic periods.
Cognitive behavioral task
Cognitive performance was monitored 3–5 days a week using a
previously described behavioral test (Vezoli et al., 2011). Brieﬂy,
Fig. 1. Experimental protocol and timeline. A. Four animals were used in the study and grouped according to their clinical state in control (n=4, cases 1–4); premotor (n=4, cases 1–4);
spontaneously recovered (n= 2, cases 1 and 3); stable symptomatic (n= 4, cases 1–4). Cases that recovered following MPTP-injections offset entered a secondMPTP phase in order to
induce a stable parkinsonian state. B. Longitudinal evolution of the clinical score (in weeks) through the protocol for all cases; score has been aligned to the last MPTP-injection. PET-scan
week sessions are depicted in blue. Clinical score for cases 2 and 4 are plotted twice; the ﬁrst MPTP intoxication (in dashed lines) was also the last MPTP and used in the premotor group.
Red arrowheads indicate the beginning of MPTP intoxication for each case.
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cesses (retrieval of reward on the ﬁrst reach, over the total number of
trials) and errors (barrier hits, over the total number of responses ob-
served—there could be several responses per trial except in the case of
success). Errors due to motor impairments were classiﬁed as such and
further discarded from the performance evaluation, so as to avoid con-
founds due to the symptomatic state of the animal. The performance
on the ‘detour task’ depends on the integrity of frontal cortex, the dopa-
minergic system and DA innervation of frontal cortex (Diamond, 1996)
and has been used to assess the impact of lesion of the nigrostriatal axis
on cognitive performance as well as potential therapy for cognitive im-
pairments (Schneider et al., 1998; Taylor et al., 1990a, 1990b).[11C]PE2I binding potential evaluation
To evaluate the in-vivo DA function, images from PET scans using (E)-
N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4′-methylphenyl)-
nortropane labeled with carbon 11 ([11C]PE2I) were obtained at different
intervals throughout the protocol. [11C]PE2I speciﬁcally binds with high
afﬁnity and selectivity to DAT (Ki = 17 nM) and is considered to provide
an index of the integrity of the DA pathway that has been used for PD
diagnosis (Emond et al., 1997; Poyot et al., 2001; Shih et al., 2006
for a review). [11C]PE2I PET studies were performed with an ECAT
Exact HR + tomograph (Siemens CTI), in 3D acquisition mode, cov-
ering an axial distance of 15.2 cm. The transaxial resolution of thereconstructed images was about 4.1 mm full-width and half maxi-
mum in the center. Transmission scans were acquired with three ro-
tating 68Ge sources and were used to correct the emission scans for
the attenuation of 511 keV photonrays through tissue and head
support.
[11C]PE2I labeling
PE2I was labeled with carbon 11 (cyclotron–produced isotope, half-
life = 20.4 min) at its methyl-esther function from the corresponding
carboxylic acid precursor and the highly efﬁcient methylating reagent
[11C]methyl-triﬂate. Typically, 7.4 to 11.1GBq of [11C]PE2Iwere routine-
ly obtained within 25 min of synthesis, with speciﬁc radioactivity rang-
ing from 29.6 to 44.4 GBq/μmol. Radiochemical and chemical purity of
[11C]PE2I (as determined by HPLC) was above 98% (Poyot et al., 2001).
PET examination
Anesthesia of the monkeys was induced with 15 mg/kg Zoletil
(Tiletamine and Zolazepam, Virbac, Carros, France) 30 min after
premedication with 0.1 mg/kg atropine sulfate. A MRI-compatible ste-
reotaxic frame (Kopf, CA, USA) was used to secure the head during the
PET scan and reduce variability in the measure. A cannula was inserted
in the femoral vein. [11C]PE2I (74 to 111 MBq) was injected as a bolus
over a 4 s period followed by a saline ﬂush. Radioactivity was measured
in a series of 24 sequential time frames of increasing duration (from
30 sec to 10 min; total time 70 min).
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Based on anatomical-MRI andmaximumprobability atlas (Ballanger
et al., 2013), 88 ROIs were deﬁned and used to follow binding potential
on PET-scans for these regions throughout the protocol; here we fo-
cused on striatal structures (10 ROIs—(see Supplementary Fig. 1), ante-
rior–posterior caudate nucleus and putamen and the ventral striatum).
We additionally document changes in DAT binding for the cortical re-
gions showing substantial amount of binding (cingulate cortex) and
through the three main periods: premotor, motor-recovered, and
motor-symptomatic. Anatomical MRI acquisition was performed in a
different session and consisted of a 3D anatomical T1-weighted se-
quence using a 1.5-T Siemens Magnetom scanner (Siemens AG, Erlang-
en, Germany). The anatomical volume covered the whole brain with
0.6 mm cubic voxels. Each PET scan was summed over frames, before
being registered between PET acquisitions to provide a mean PET
image. The mean PET images were manually pre-registered to the ana-
tomical individual MRI based on anatomical landmarks (anterior com-
missure, left and right orbital center, left and right caudate head, left
and right posterior ventral putamen using the graphic application regis-
ter—MINC-toolbox) in order to compute a rigid transformation that was
then used as a starting point for positioning theMRI and PET images be-
fore the following automated procedure. Individual MRI scans were
then registered to our Fascicularis MRI template (Ballanger et al.,
2013). Transformations from native PET to individual MRI and individ-
ual MRI to template were concatenated in order to provide direct (and
inverse) afﬁne transformations from PET native spaces to the template
space. With these transformations, see (Ballanger et al., 2013) for a de-
scription of procedures, the brain fascicularis maximum probability
atlas was then propagated to PET native spaces so as to allow extraction
of regional PET time activity curves (TACs) of the 88ROIs. Quantiﬁcation
of regional [11C]PE2I non-displaceable binding potentials (BPND) was
performed using the simpliﬁed reference tissue model (SRTM)
(Lammertsma and Hume, 1996). Time activity curves of the cerebellum
(excluding the vermis) were used as the reference for the SRTM (Seki
et al., 2010). SRTM modeling provided three macro-parameters: BPND,
k2 (rate constant for transfer from the tissue to the plasma compart-
ment) and R1 (ratio of the K1 rate constants of the target region and
the reference region, K1 being the transfer rate from the plasma to the
tissue compartment). Parametric images of BPND were computed at
the voxel level with right and left averaged cerebellum TACs as refer-
ence region. Because the registration procedure is semi-automated,
we repeated the procedure three times for each case in order to account
forwithin-measure variance (for each case, 2 ROIs per hemispherewere
used for caudate and putamen and one for the ventral striatum).
In case 1, for the premotor scan, curves of Bq/cc ﬁxation over scan-
time produced proﬁles for ROIs that did not attain a plateau and showed
slight increases over successive frames of this session. Thus, it could be
assumed that the equilibrium between the free and unspeciﬁc binding
compartments was not reached (Costes et al., 2007). Another possible
explanation is that the ROI TAC has averaged voxel TACs with different
patterns such that SRTM could not evaluate BPND values at the ROI level.
Alternatively, BPND were also computed at a voxel level. Voxel TACs
were submitted to the SRTMmodelingwith the cerebellum as reference
region, providing parametric image of BPND.
Identical quantiﬁcation procedures for control and premotor scans
were used for both group and individual comparisons. Maximum and
averaged values of voxel BPND per ROI (caudate, putamen and ventral
striatum for left and right hemisphere)were extracted and used to com-
pute relative binding difference between scans in the same subject. Be-
cause maximum voxel-level BPND per ROI could be potentially fraught
with noise, we compared them tomean voxel-level BPND per ROI (Sup-
plementary Fig. 2). This shows that: i) maximum and mean voxel-level
BPND per ROI are highly correlated with ROI-level BPND but maximum
voxel-level BPND is closer to ROI-level BPND, ii) maximum and mean
voxel-level BPND assume identical statistical test result concerning in-
creased DAT-binding in the early_MPTP effect (+22.7 ± 5.6% and+18.6 ± 2.9%, relative change compared to control for maximum and
mean voxel-level BPND respectively) and iii) maximum and mean
voxel-level BPND are highly correlated (R = 0.95, p = 4.7E−6). Note
that our conclusions on the early_MPTP results are based on the aver-
aged voxel-level BPND. Maximum voxel-level BPND was extracted here
only to show the correspondence with ROI-level BPND.
Parametric BPND images of the early_MPTP period were spatially
normalized to stereotaxic space in order to perform voxel-by-voxel sta-
tistical analysis with SPM8 (Welcome Trust Centre for Neuroimaging,
London, UK) presented in Fig. 3D. Case 4 could not be included in the
premotor group because its PET-images were qualitatively altered due
to the incidental presence of the infusion line in the ﬁeld of view of
the PET camera, thereby excluding further statistics with other scans.Regional assignment of PET changes
In order to visualize themaps of [11C]PE2I-BPND changes subsequent
toMPTP intoxication (Supplementary Fig. 3), we performed subtraction
of control from early_MPTP parametric BPND images (after spatial nor-
malization to template space) for each case before averaging as group
data. The observed decrease in DAT binding was more focused than
the DAT increase and consistently localized in the posterior part of the
atlas-deﬁned left posterior putamen (Supplementary Fig. 4); therefore,
the DAT increase (in the anterior part) oversized and masked the DAT
decrease (in the most posterior part) at the ROI-level. We used the
2.5th percentile of the overall brain distribution of difference voxel-
level values (Supplementary Fig. 5) to describe regions of signiﬁcant de-
crease in DAT binding (values inferior to−0.39, Fig. 2B); whereas the
97.5th percentile was used to describe regions of signiﬁcant increase
in DAT binding (values superior to +0.54, Fig. 2A). The same method
was applied for each individual case in the early_MPTP condition (Sup-
plementary Fig. 5) and for the other conditions (post-MPTP recovered
and symptomatic) to deﬁne statistical threshold in parametric maps of
the difference in BPND between two given conditions.
For each case, a PET was done in the control period (prior to MPTP
intoxication) and used to compute the change relative to control for
all periods (early_MPTP, post-MPTP recovered and symptomatic).
Individual cases data are reported in Supplementary Table 5 for the
early_MPTP condition.
Control levels of cortical [11C]PE2I-BPNDwere in average 91.2% lower
than striatal levels. However, the top 5% of cortical DAT bindingwas not
different from the lowest 5% of striatal DAT binding (ranksum, p N 0.05).
We therefore document changes for the top 5% of cortical DAT binding
which was located in the limbic cingulate cortex ROI (Ballanger et al.,
2013).Immuno-histological procedures
Three age and weight matchedM. fascicularis, served as controls for
the three cases processed (cases 1, 3 and 4). Deep anesthesia was in-
duced with Ketamine after premedication with chlorpromazine hydro-
chloride (Largactil) followed by a lethal dose of pentobarbital sodium
(Vibrac, 100 mg.kg−1, i.p.; conﬁrmed by complete loss of corneal reﬂex)
before animals were transcardially perfused with saline (0.9% with
procaine) and 4% paraformaldéhyde and 0.05%-glutaraldehyde in
phosphate buffer. Cryoprotection was ensured by sucrose gradients
(10–30%) perfusion post-ﬁxation. Brains were removed, kept in
cryoprotecting liquid overnight and coronal 50 μm thick sections cut
on a freezingmicrotome. Sections were processed together with equiv-
alent sections from control animals for Tyrosine Hydroxylase (TH;
Millipore, #MAB318) and DAT (Millipore, #MAB369) immunochemis-
try visualized with 3,3-diaminobenzidine, in Ni2 + H202 (0.5-1.0%).
All sectionswerewashed,mounted, dried, and dehydrated in increasing
gradients of ethanol, cleared in toluene, mounted with mounting medi-
um and cover slipped.
Fig. 2. Changes in striatal [11C]PE2I binding to DAT in early phase of MPTP-intoxication. EarlyMPTP-intoxication results in anterior increase (A) and posterior decrease (B) in striatal [11C]
PE2I-BPND. Group (n=3, cases 1–3) parametric maps of BPND images result from difference between control scans and scans made in the early_MPTP condition. A. Left, sagittal views of
left and right hemisphere at the maximum signiﬁcant positive difference (increased binding); right, coronal views corresponding to anterior and posterior lines in middle ﬁgure (axial
view). B. Left, sagittal view (top) and coronal view (bottom) at themaximum signiﬁcant negative difference (decreased binding) in the left posterior putamen (right). C. Increase and de-
crease in [11C]PE2I-BPND shownwith the same scale. White arrows indicate site of decrease in binding to DAT. Color scale corresponds to [11C]PE2I-BPND level (arbitrary units) from the dif-
ference early_MPTP vs. CTR.
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Evaluation of the extent and amplitude of the nigrostriatal lesion
was obtained with semi-quantitative immunohistochemistry (Dzahini
et al., 2010) of the striatal structures. The mean optical density (O.D.)
of TH and DAT immunoreactive regions were computed on at least 5
sections per animal (5–20) from 8bit images, normalized and compared
with two-sample t-test separately for each ROI (ttest2, Matlab). In Sup-
plementary Figs. 7–8 the composite CTR and MPTP images have been
enhanced for brightness and contrast, for illustration purpose.
Statistics
Data were ﬁrst grouped according to MPTP dosage in order to de-
scribe behavioral performance at the very early stages ofMPTP intoxica-
tion (when no clinical symptomswhere observed i.e. clinical score null)
(Fig. 3C). We then separated MPTP and post-MPTP periods into ﬁve
equal epochs and grouped variables in each. This segmentation method
(Vezoli et al., 2011) better reveals normalized stages of disease progres-
sion thereby allowing comparison of different parameters across an
equivalent number of epochs for all subjects. These epochs are referred
as quantiles (Figs. 3–5). Results are presented as means ± standard
errors.
Parameters were compared to control values by a treatment-
contrast test using control measures as the ﬁrst level (estimated stan-
dard errors and z-ratiowere computed usingGLMﬁt and contrast result
was given by two-tailed p-values corresponding to z-ratio based on a
Student t-test). Signiﬁcance was considered at p b 0.05. Statisticalanalyses were computed using R software (R Foundation for Statistical
Computing, Vienna, Austrian http://www.R-project.org) and the sum-
mary function (Chambers, J. M. andHastie, T. J. (1992) StatisticalModels
in S. Wadsworth & Brooks/Cole).
Results
Control scans returned comparable BPND values across animals as es-
timated at the ROI-level (Supplementary Table 2) or voxel-level and
these different values showed signiﬁcant correlation (Supplementary
Fig. 2).
Alterations of [11C]PE2I-BPND during MPTP-treatment and relation to
emerging non-motor cognitive symptoms
Surprisingly, the early effect of MPTP, during the so-called premotor
period, was characterized by a marked increase of striatal [11C]PE2I-
BPND in all cases tested (+18.6 ± 2.9%, percent change from control,
mean voxel-level BPND per ROI). Following control scans, PET images
of [11C]PE2I binding to DAT were obtained in 3 animals (cases 1–3) 3–
5 days after the ﬁrst two weeks of MPTP intoxication (total cumulative
dose 0.6 mg/kg). In all cases there was a consistent increase of [11C]
PE2I-BPND levels in the striatum (mean voxel-level BPND, Supplementa-
ry Table 5). These increases were signiﬁcant at both group (Figs. 2A, 3B,
D) and individual levels (Supplementary Figs. 3–4). Group values of
voxel-level BPND per ROI after 3 injections of MPTP show an increase
that looks slightly more pronounced in the right putamen (Fig. 3B).
Fig. 3. Early [11C]PE2I-BPND increase accompanied by deterioration of behavioral performance in absence ofmotor deﬁcits. A. Clinical score during early phases of MPTP-intoxication for the
group (n=3, cases 1–3). Arrow indicates that PET-scans were made while nomotor deﬁcits were observed. B. Boxplots of group value of the difference in voxel-level SRTM estimates of
DAT binding between the control (CTR) condition and the second week of MPTP-intoxication (early_MPTP) in the different striatal structures. C. Behavioral performance for the group in
control condition, theweek following ﬁrstMPTP-injection (3MPTP injections in total), the secondweekwhen PET-scanwasmade (blue arrow) and a periodwhen 3moreMPTP-injections
weremade. D. Structural Probability Map (n=3) analysis showing regional focus of earlyMPTP effect on striatumprior tomotor symptoms (pre-symptomatic stage). Color scale: T-score.
Statistics refer to a contrast test with CTR as the ﬁrst level, ns: non-signiﬁcant, *: p b 0.05, **: p b 0.01, ***: p b 0.001. Note the x-axis in A refers to Quantiles (seeMethods section for deﬁnition).
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BPND images (Fig. 2A) exhibit a signiﬁcant DAT increase focused on
the left anterior putamen (SPM results with a voxel height threshold
of T= 1.66, comparing early_MPTP vs. CTR: k= 18.62 mm3; T= 2.28
and 3.56, P = 0.019 and 0.002 (uncorrected, no extent threshold) for
right and left striatum respectively). Importantly, the statistical maps
also exhibit a signiﬁcant decrease of DAT binding in the left posterior
putamen (Fig. 2B). Thus, averaging the lateralized increase and decrease
in one atlas ROI obscures the ﬁnding of a more pronounced increase in
the left anterior putamen. This was even more pronounced when con-
sidering anterior and posterior ROIs of caudate and putamen (Supple-
mentary Fig. 6). Both group (Fig. 2.A) and individual (Supplementary
Fig. 4) parametric images of difference in BPND conﬁrm that the broad
striatal [11C]PE2I-BPND increase is an unambiguous feature of the initial
phase of the MPTP-treatment during which the nigrostriatal insult is
supposedly modest. The distribution also shows that the decrease of
DAT binding is much more restricted. This [11C]PE2I-BPND decrease in
the early_MPTP condition was consistently involving a sub-part of the
posterior putamen (Fig. 2B). The presence of a consistent localized de-
crease of [11C]PE2I-BPND in the posterior putamen (sub-part of the left
posterior putamen, see Supplementary Fig. 4) suggests that the ob-
served broad increase in the more anterior striatal DAT binding reveals
an intrinsic compensatory mechanism of the DA system at the very
early stages of the nigrostriatal lesion.Because we used systemic injections of MPTP, we veriﬁed if the lat-
eralization of the early response to MPTP could stem from an already
present asymmetry in the control scans. CTR scans showed that left stri-
atumpresented overall+1-4%moreDATbinding compared to the right
striatum but this was not signiﬁcant considering the whole striatum
(signtest, left vs. right: p = 0.1539 for mean voxel-level BPND). This
inter-hemispheric asymmetry depended only on the putamen for
which the left side had +6.0 ± 3% more DAT binding compared to
the right side (percent change for mean voxel-level BPND; signtest, left
vs. right: p b 10−4 for mean voxel-level BPND).
As expected, cognitive behavior symptoms emerged gradually
throughout the course of MPTP intoxication. However, the error rate
was signiﬁcantly altered only in the period following 3 MPTP injections
(Fig. 3C)—a period when no motor symptoms were observed (Fig. 3A).
This coincided with the observed increase and decrease of DAT binding
in the relatively more cognitive region of the striatum i.e. anterior stria-
tum (Haber, 2003) and in the motor region i.e. posterior putamen, re-
spectively. Because of the lateralization of these changes (Fig. 2), we
further separated trials of the task regarding the position of the opening
(Vezoli et al., 2011).We identiﬁed a contralateral effect of these changes
in DAT binding on cognitive performance deterioration i.e. performance
on the right side of the animal was signiﬁcantly alteredwhereas perfor-
mance for the left side was not (Fig. 3C). This effect was clear only dur-
ing the early_MPTP period i.e. following 3 MPTP injections. With
Fig. 4.MPTP effects on [11C]PE2I binding to DAT and behavioral performance following spontaneous motor recovery. A. Changes in clinical score (during and after MPTP) of cases that
spontaneously recovered following arrest ofMPTP-intoxication (n=2, cases 1 and 3). Arrows indicate PET-scan periods (values reported in B). B. Boxplots of group value of the difference
in ROI-level SRTM estimates of DAT binding between the control (CTR) condition and post-MPTP (i) before recovery i.e. score temporarily above symptomatic threshold (t-symptomatic)
and (ii) following maximal motor recovery (recovered). C. Behavioral performance for the group during MPTP-intoxication and during motor recovery. D. Group parametric images
resulting from difference between control scans and scans made when motor recovery was maximal (clear blue arrows in A,C). Left, axial view and right, coronal views of decrease in
[11C]PE2I-BPND following spontaneousmotor recovery. Anterior (top right) and posterior (bottom right) striatal levels indicated by dashed lines on the axial view. Conventions as in Fig. 3.
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peared i.e. right and left side performances were both signiﬁcantly al-
tered. Importantly, this cannot be imputed to overt motor deﬁcits
from the right body parts as no motor errors were observed in this pe-
riod. The restricted number of cases tested (n= 3) doesn't allow us to
determine whether the [11C]PE2I-BPND increase or decrease correlated
best with deteriorated performance.
There was no signiﬁcant change in [11C]PE2I-BPND in the limbic cin-
gulate cortex for the premotor condition (CTR, right: 2.4 ± 0.8 and left:
2.9 ± 0.7 vs. premotor, right: 2.1 ± 1.3 and left: 2.4 ± 1.5 [11C]PE2I-
BPND, arbitrary units). This strengthens the hypothesis that the early
compensatory increase in DAT binding is restricted to the striatum.
However, we cannot fully exclude changes in the other cortical ROIs
with lower levels of DAT bindingmeasured with the current technique.Alterations of [11C]PE2I-BPND after MPTP-treatment and relation to induced
motor and non-motor cognitive symptoms
In order to verify the expected reduction of DAT binding after
prolonged MPTP intoxication, [11C]PE2I-BPND was longitudinally
followed subsequent to interruption of MPTP-treatment in two other
conditions (Fig. 1): spontaneous motor recovery (n = 2, clinical scoreb 5) and long-term symptomatic parkinsonian state (n = 4, clinical
score NN 5). These results are now entirely based on ROI-level BPND.
Spontaneous motor recovery
In two cases (1 and 3) MPTP injections were suspended as soon as
clinical score reached the symptomatic threshold (score N5). The clini-
cal score increased progressively and a transient symptomatic state
was observed (Supplementary Table 1), after which clinical score
returned to baseline level (Fig. 4A). Clinical symptoms emerged in the
following order: mild bradykinesia, stooped posture, rare freezing and
intermittent resting tremor for case 1; mild bradykinesia, stooped pos-
ture, intermittent resting tremor and rare freezing for case 3. PET-
scanswere performed i) at the peak of clinical score (twoweeks follow-
ing last MPTP injection), corresponding to a score around 10 and ii) at
two intervals following maximum recovery (Fig. 4A–B). [11C]PE2I-
BPND was already reduced at the peak of clinical score, during the tran-
sient symptomatic state (striatum:−58.2 ± 14.5%). Striatal [11C]PE2I-
BPND values were decreased by 71.5 ± 9.7% once maximum recovery
was reached (Supplementary Table 3). The ventral striatum was the
most preserved structure (Fig. 4B, Supplementary Table 3), consistently
with previous reports on pattern of nigrostriatal denervation both fol-
lowing chronic MPTP intoxication e.g. (Perez-Otano et al., 1994) and
in PD patients (Gibb and Lees, 1991), but still showing 60.1 ± 14.2%
Fig. 5. MPTP effects on [11C]PE2I binding to DAT and behavioral performance after induction of stable parkinsonian symptoms. A. Changes in clinical score during and after MPTP-
intoxication (n= 4, cases 1–4), aligned on last MPTP injection. Arrows indicate PET-scan period (values reported in B). B. Boxplots of group value of the difference in ROI-level SRTM es-
timates of DAT binding between the control (CTR) condition and post-MPTP after induction of a stable Parkinsonian state. C. Behavioral performance for the group during last MPTP-
intoxication and after. For cases 1 and 3, the MPTP period corresponds to last-MPTP (see Fig. 1B). D. Group parametric images resulting from difference between control scans and
scans made when motor symptoms are stably expressed (over symptomatic threshold). Left, axial view and right, coronal views of decrease in [11C]PE2I-BPND. Anterior (top right) and
posterior (bottom right) striatal levels indicated by dashed lines on the axial view. Conventions as in Fig. 3.
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[11C]PE2I-BPND was large (Fig. 4D).
While clinical score had returned to control levels, cognitive behav-
ior deﬁcits remained in the recovery period (Fig. 4C). Error rate gradual-
ly increased and success rate decreased during the MPTP period
reaching a point for which the error rate was above the success rate.
After MPTP injections were stopped, this decline in cognitive behavior
performance worsened during clinical motor recovery (Quantiles Re-
covery 1–2 i.e. 5–6 weeks post-MPTP, Fig. 4C). Once maximum motor
recovery was reached, performance tends to improve but still remained
signiﬁcantly deteriorated conﬁrming previous results (Vezoli et al.,
2011). Importantly, while errors due to pure motor symptoms are care-
fully discounted in the calculation of error rate such that increasing
error rate is not linearly related to the degree of motor impairments,
we cannot rule out that motor symptoms might have speciﬁcally inﬂu-
enced motor planning during the transient symptomatic phase.
In recovered cases, limbic cingulate cortical DAT levelwas signiﬁcantly
reduced compared to control (CTR, right: 2.1 ± 0.8 and left: 2.7 ± 0.6 vs.
motor-recovered, right: 1.1± 0.4 and left: 1.0± 0.3 [11C]PE2I-BPND, arbi-
trary units; signtest, p= 0.03 for right and left hemisphere).Stable Parkinsonism
In all cases (n=4) theMPTP-protocols gave rise to a long-lasting, sta-
ble parkinsonian syndrome (Fig. 5A). For the animals that spontaneously
recovered following arrest of the initial MPTP-treatment, a second period
of intoxication was pursued in order to obtain a persistent symptomatic
state. Clinical symptoms emerged in the following order: stooped pos-
ture, mild bradykinesia, rare freezing and intermittent resting tremor
for case 1; intermittent resting tremor, mild bradykinesia, mild rigidity,
stooped posture and rare freezing for case 2; rare freezing, intermittent
resting tremor, stooped posture and bradykinesia worsening for case 3;
mild bradykinesia, stooped posture, rare resting tremor and rare freezing
for case 4. Scans were performed while monkeys were stably expressing
parkinsonian motor symptoms (Quantile Symptomatic 3–5, Fig. 5A–B)
i.e. at least more than seven weeks following the last MPTP injection.
[11C]PE2I-BPND levels in all striatal structures weremassively affected
(Figs. 5B,D) aswell as in the limbic cingulate cortex (CTR, right: 2.5± 0.8
and left: 2.8±0.7 vs. motor-symptomatic, right: 0.7±0.2 and left: 0.8±
0.4 [11C]PE2I-BPND, arbitrary units; signtest, p=7.6E−06 for right and
p = 1.5E−05 for left hemisphere). The ventral striatum was again the
most preserved striatal region (Supplementary Table 4).
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change from control) was the only one which correlated signiﬁcantly
with clinical score after induction of stable Parkinsonism (R=−0.96,
P b 3.3E−4). This suggests that the relatively spared ventral striatum
constitutes the remaining pool of nigrostriatal terminals involved in
late compensation. Compared to [11C]PE2I-BPND levels obtained after
clinical recovery, the values obtained in the stable symptomatic period
(for these two cases) were further decreased by 31.2 ± 4.9% (Fig. 6).
Cognitive performance was dramatically and persistently altered
following MPTP-intoxication (Fig. 5C).
Post-mortem evaluation of the nigrostriatal lesion
Immunohistological precipitations were carried out on sections from
three of the four animals treated (cases 1, 3 and 4; Supplementary
Figs. 7–8 and Supplementary Table 6). Immunohistochemistry conﬁrmed
that MPTP intoxication caused severe deterioration of the nigrostriatal
pathway. In the striatum TH and DAT labeling were reduced by about
60% and 70%, respectively (Supplementary Fig. 8). TH and DAT depletion
was overall quantitatively similar between cases. However, some pre-
sented relatively more spared accumbens (Supplementary Fig. 7) and
mesencephalum. Importantly, decreased levels of striatal DAT O.D. com-
pared to controls (Supplementary Table 6) were consistent with the de-
crease of DAT as evaluated in-vivo by PET (Supplementary Table 4).
Discussion
Our data have revealed an important increase in [11C]PE2I-BPND dur-
ing the initial stages of MPTP intoxication. At this stage animals were in
the premotor period yet they presented non-motor cognitive symp-
toms. Below we propose that the increase in striatal DAT-binding we
observed during the premotor phase of MPTP-monkeys is a very early
adaptive mechanism triggered at the level of remaining DA terminals.
Further research on this physiological manifestation might warrant its
use as an additional premotor PD marker (Mossa et al., 2012; Ziebell
et al., 2012).
The broad increase of DAT binding in the caudate and anterior puta-
menwas accompanied by a decrease of DATbinding in amore restricted
part of the posterior putamen. The current data do not permit us to posit
separate causes for the local decrease but general increase of DATFig. 6. Comparison between recovered and symptomatic state. A. Boxplots of group value (n=2
toms and after induction of a stable Parkinsonian state. B. Group parametric images resulting fr
symptoms were stably expressed. Left, axial view and right, coronal views of decrease in [11C]P
right) striatal levels indicated by dashed lines on the axial view. Statistics refer to a paired, two-s
signtest), *: p b 0.05, **: p b 0.01, ***: p b 0.001).binding in the striatum. Complementary approaches would be required
to test whether, for example, the local decrease is a sign of moderate
local ﬁber loss, and if the substantial increase is a compensatory mech-
anism in the rest of the striatum.We additionally showed that the early
response to dopaminergic lesion in the premotor phase is signiﬁcantly
lateralized: the increase and the decrease of [11C]PE2I-BPND were
more signiﬁcant in the left anterior and left posterior putamen respec-
tively. Behaviorally, we did not observe a lateralization of the onset of
motor deﬁcitswith our clinical rating scale.Most probably,more precise
evaluation is needed in order to make the link during this premotor
phase (Picillo et al., 2013). However, we identiﬁed a contralateral effect
on cognitive performance deterioration. Even if no motor deﬁcit were
observed (i.e. clinical motor score null), the decrease of DAT binding
in the left posterior putamen might have had an inﬂuence on motor
control which would add to the increase of DAT binding in the caudate,
ventral striatum and anterior putamen and its probable consequences
on cognitive functioning. This is coherent with studies describing how
reduced or excessive prefrontal DA can equally or differentially affect di-
verse cognitive functions (Cools, 2006; Cools et al., 2001; Cools and
d'Esposito, 2011; Floresco, 2013). We can reasonably argue that the
emergence of a speciﬁc variety of premotor cognitive deﬁcits might
well correlate with a dopaminergic hypertonia in the caudate, ventral
striatum and anterior putamen (Leviel, 2011). Under the assumption
that the [11C]PE2I-BPND decrease reﬂects an initial nigrostriatal lesion,
this would lead to an increase in DA synthesis and release of remaining
DA terminals (Zigmond et al., 2002). This hypertonic DA state could
have a direct role in deteriorated cognitive performance (Cools, 2011;
Cools et al., 2003). However, it can also be argued that the hypertonic
DA state induces a compensatory DAT overexpression (Jakowec et al.,
2004) at the levels of the remaining DA terminals which could lead to
increased impulsivity (Costa et al., 2013). Further research is required
in order to identify whether the deteriorated cognitive performances
can be imputed to the large DAT binding increase in the caudate, ventral
striatum and anterior putamen or to the more restricted DAT binding
decrease in the posterior putamen that we report here on a restricted
number of cases.
The asymmetrical manifestation of motor symptoms in PD patients
is well recognized and used as a hallmark of Parkinson's disease
(Marek et al., 1996), and a recent SPECT study in humans PD patients
showed a lateralization of DAT availability in the posterior putamen, cases 1 and 3) of ROI-level SRTM estimates of DAT binding after recovery of motor symp-
om difference between scans made when motor recovery was maximal and when motor
E2I-BPND following second MPTP-intoxication. Anterior (top right) and posterior (bottom
ided sign-test between percent change from CTR of MPTP recovered and Symptomatic (matlab,
258 J. Vezoli et al. / NeuroImage 102 (2014) 249–261(Scherﬂer et al., 2012). However, this is to our knowledge the ﬁrst time
the latter is demonstrated in the systemic MPTP-model of Parkinson's
disease (Blesa et al., 2011). We provide evidence that this lateralization
in the premotor phase might to a large extent depend on the inter-
hemispheric difference present in control scans, as the side with the
highest labeling was the most affected following MPTP injections. This
is coherent with the view that DA terminals presenting more DAT
show increased sensitivity to subsequent intoxication (Bannon, 2005).
This needs further conﬁrmation and if this is the case longitudinal mon-
itoring of human patient populations presenting identiﬁed risks for the
development of PD might be envisioned (Mossa et al., 2012; Ravina
et al., 2012; Ziebell et al., 2012).
We speculate that the initial DA cell death produced by MPTP causes
externalization of the DAT sites responsible for DA release induced by
the local enhancement of the glutamate metabolism acting on glutamate
receptors located on the striatal DA terminals (Johnson and Jeng, 1991).
Importantly, a recent study conﬁrmed the potentially harmful role of glu-
tamate (Masilamoni et al., 2011), showing that glutamate receptor antag-
onist has signiﬁcant protective effects onmidbrainDAneurons. This study
also reported a transient striatal 18F-FECNT increase but, in this case, the
increase in measured DAT binding might possibly be more related to
compensatory sprouting given longer time delays (Song and Haber,
2000). We observed that similar increases of striatal DAT binding can be
greatly prolonged over months with extended low-frequency/low-dose
protocols (Unpublished results). As a consequence, this very early in-
crease in the striatal [11C]PE2I-BPNDwas detectable before the occurrence
of signiﬁcantmotor symptoms. Further investigations are needed in order
to conﬁrm the duration of this early DAT compensation on a longer time-
scale following MPTP-injections cessation and to delineate a therapeutic
index. Such studies will give a better indication of the relevance of the
present acute ﬁndings to the neurodegenerative processes occurring in
PD over very extended periods.
Beyond the earlyMPTP condition and, in order to verify the expected
reduction of DAT binding after prolonged MPTP intoxication, [11C]PE2I-
BPND was followed subsequent to i) spontaneous motor recovery and
ii) long-term symptomatic parkinsonian state. Monkeys that spontane-
ously recovered from motor deﬁcits presented greatly reduced striatal
DAT binding, as recently shown in-vivo with other radiotracers (Blesa
et al., 2010, 2012). While clinical score improves during this period,
DAT binding as measured with [11C]PE2I-BPND declines, thus demon-
strating a clear dissociation between clinical scores and DAT binding.
This supports theories of compensatory mechanisms harmful for DA
cells. Speciﬁcally motor compensation may involve mechanisms which
generate byproducts that are harmful for the delicate DA cells population
(Bezard et al., 1997a, 1997b; Dzahini et al., 2010; Leviel, 2011). Further-
more, this calls for a better distinction between the premotor and recov-
ered animals. While both groups are clinically below the motor
symptomatic threshold and express non-motor cognitive symptoms,
they have clearly different levels of DAT binding which implies the en-
gagement of different compensatory systems: DAT compensation in
premotor animals and, according to the literature, non-DAT compensa-
tion in recovered animals (Boulet et al., 2008; Larsen et al., 2011; Smith
and Greene, 2012). We argue that non-DAT compensatory mechanisms
still rely on a minimal amount of DAT or nigrostriatal DA ﬁbers because
high clinical scores were correlated with considerably lowered levels of
DAT only after the induction of a stable parkinsonian state. We show
that the only striatal region that was signiﬁcantly correlated to the de-
gree of motor impairments was the ventral striatum. Low levels of DAT
binding are coherent with a reduction of nigrostriatal DA terminals fol-
lowing repeated MPTP injections (Bannon, 2005; Donovan et al., 1999).
This could also be explained by a change in DAT trafﬁcking dynamics be-
tween plasmalemme and endosome (Chen et al., 2010; Mortensen and
Amara, 2003). Otherwise, we cannot exclude the involvement of non-
DAT compensatory mechanisms but using probably transporters from
the same family e.g. serotonin et noradrenaline (Larsen et al., 2011;
Moron et al., 2002; Smith and Greene, 2012).In the following, we review the possible adaptive processes involved
in early and late phases ofMPTP intoxication and in particular, concerning
the observed 19–23% increase in [11C]PE2I-BPND in the early phase:
i) a global increase of the number of DA terminals exceeding the
pretreated state seems less likely than a small reduction in theni-
gral DA cell population and striatal DA innervation; possibly less
than after partial lesions of the nigrostriatal DA pathway in ani-
mals (Dzahini et al., 2010) and certainly smaller than in the
early phases of PD investigated in humans. Our observation of a
localized decrease inmeasuredDATbinding in a restricted region
of the posterior putamen suggests that the lesion following three
MPTP injections corresponds to a moderate insult of the
nigrostriatal system. Even if moderate, the DA innervation can
only be reduced and cannot explain the increased [11C]PE2I-
BPND. Sprouting of the surviving nigrostriatal terminations has
been reported for longer delays after MPTP-intoxication offset
(Song and Haber, 2000; Stanic et al., 2003). However, further in-
vestigations of the delay after last MPTP injection need to be
done in order to conﬁrm compensatory sprouting of DA ﬁbers.
Reported delays of 4–5 weeks (Song and Haber, 2000) for DA
sprouting make this phenomenon unlikely to contribute to the
increase in external DAT sites we observed 3–5 days following
last MPTP injection.
ii) Following partial lesions in animals and during early phases of
degeneration there is an activation of DA metabolism and a re-
duction of DA uptake (Bezard et al., 2000; Gerhardt et al., 1996;
Stanic et al., 2003). These observations are completed by recent
ﬁndings of increased DA and glutamate release in the striatum
of rats with restricted 6-OHDA lesion in the SN (Dentresangle
et al., 2001; Dzahini et al., 2010). Note MPTP reduces the ability
of DAT to uptake DA through a competitive process. Thus, an in-
creased afﬁnity of the DAT external uptake sites is unlikely to be
involved in the increased [11C]PE2I-BPND we report here.
iii) the process by which DA is tonically released in the striatum is
known to involve DAT (Jakowec et al., 2004; Leviel, 2011) and
an enhancement of this process could increase the availability
of external DAT-sites for [11C]PE2I binding. This hypothesis
could explain both the increased DA release observed after re-
stricted lesion of the SN and substantiate the role of glutamate
in this process. Glutamate transmission is clearly related to
changes in DAT functions and to the DAT-dependent DA release
in the striatum (Dentresangle et al., 2001; Dzahini et al., 2010).
Glutamate increase in the striatum might combine with DAT in-
crease to constitute an initial compensatory activation of synthe-
sis and release of DA (Chuhma et al., 2004; Hnasko et al., 2010).
However, glutamate increase has been shown to be a detrimen-
tal consequence of the nigrostriatal DA lesion (Dzahini et al.,
2010; Masilamoni et al., 2011). Further, the initial DAT increase
might sensitize DA terminals to subsequent intoxication
(Bannon, 2005; Jakowec et al., 2004). The lateralization in CTR
scans is coherent with this view as the initial DAT decrease was
also lateralized and affected primarily the left putamen which
was displaying more DAT binding than the other hemisphere in
CTR scans. Together, these results argue in favor of idiopathic
parkinsonism possibly resulting from repeated small insults to
the DA system that are ampliﬁed over time due to intrinsic DA
compensation (Braak et al., 2003; Broussolle and Thobois,
2002; Calne, 1992; Calne and Langston, 1983). Recent reports
suggest that acting on this early and potentially harmful adaptive
process could provide protection from further neurodegenera-
tion (Masilamoni et al., 2011).
iv) DAT belongs to the same class of solute carrier as serotonin,
GABA and norepinephrine transporters (Amara and Kuhar,
1993). Hence, DA cell death could lead to the recruitment of
other neurotransmission systems thereby contributing to the
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in accordance with the known shift of phenotype of striatal
GABAergic neurons of macaque monkeys after MPTP intoxica-
tion (Tande et al., 2006). However, the time required for such a
phenomenon (tested 4–5 weeks after the last MPTP injection)
and the required size of the lesionmake this hypothesis relative-
ly unlikely.
v) Glial cells could also contribute to the observed phenomena. Glial
cells expressDAT and it is known that neurodegeneration in PD is
associated with prominent neuroinﬂammation where glial cells
play a crucial role (Annese et al., 2012; Cicchetti et al., 2002;
Takagi et al., 2007; Vazquez-Claverie et al., 2009; Villalba and
Smith, 2011).
Concerning the late phase, following interruption of the MPTP-
treatment, functional recovery has been characterized by increased
TH protein-mRNA (in the ventral striatum and mecencephalon)
and unchanged DAT protein-mRNA (in the striatum and ventral
mecencephalon) (Rothblat et al., 2001). However, we identiﬁed higher
in-vivo DAT values in the striatum of motor recovered compared to
symptomatic cases, consistent with previous reports on post-mortem
DAT levels (Blesa et al., 2012; Mounayar et al., 2007). Various mecha-
nisms could be involved in this process and might be more related to
the late phase of premotor or preclinical Parkinsonism. The extent of
DAneuron loss in PD correlateswith levels of DAT expression in speciﬁc
brain regions (Bannon, 2005). Hence it is believed that regions of low
DA innervation (e.g. the ventral striatum) become critically involved
in late compensatory mechanisms by constituting the surviving pool
of DA neurons upon which non-DA compensation relies to be efﬁcient.
Sprouting of dopaminergic and/or serotoninergic ﬁbers has also been
reported (Boulet et al., 2008) following MPTP intoxication; although
the amplitude of these effects appears too limited to entirely explain
the near complete functional recovery observed in the present study.
Moreover, a recent study favors the role of preserved DA terminals rath-
er than the serotoninergic system in spontaneous recovery (Neumane
et al., 2012). Nonetheless, altered cortical serotonin levels could have
contributed to changes in behavioral performance for the task used
(Walker et al., 2006). Further investigations are needed to determine
whether the serotoninergic system is implied earlier than previously re-
ported (Boulet et al., 2008; Neumane et al., 2012) and could have also
contributed to behavioral changes observed during the pre-motor
stage. Lastly, increased dopa-decarboxylase activity at DA terminals
has been shown to play a compensatory role in nigrostriatal denerva-
tion (Brooks et al., 2003) and to explain why PET-scans using [18F]
DOPA are less sensitive than DAT-scans to conﬁrm DA denervation
(Ribeiro et al., 2002). Further research is needed to focus on this period
(Vezoli et al., 2011), as the processes involved are most probably
mirroring those at play during late compensation in PD. Subcortical sys-
tems are likely to be implicated in the compensatory processes (Piﬂ
et al., 2013); however, alterations of motor control remain well corre-
lated to the severity of the degenerative process of the nigrostriatal
pathway.
Conclusions
This study shows that DAT is differentially regulated after partial le-
sion and according to the level of DA neuron insult (Afonso-Oramas
et al., 2010). It can be concluded that the very early consequence of a
mild MPTP intoxication and the associated nigrostriatal denervation in-
duces the 19–23% increase of the [11C]PE2I-BPND on the DA terminals of
striatal structures we observed in the macaque monkey. This is likely
due to an increase of the number of DAT sites known to cause the
local DA overﬂow following mild nigrostriatal denervation. This could
allow transient regulation of DA homeostasis at the onset of the MPTP
intoxication in monkeys and possibly during preclinical phases of
Parkinson's disease. Further conﬁrmation of this phenomenon haspotential clinical applications in the early detection of the ongoing DA
lesion and optimizing treatment of the disease. This very early adaptive
mechanism is probably triggered at the level of the DA terminals, and
could be harmful in the long-term due to interactions with glutamate
transmission. These mechanisms could both persist but differ from
those at play during behavioral recovery i.e. long-term compensation.
Our results conﬁrm that compensatory mechanisms can lead to normal
motor behavior inMPTP-monkeys, despite a reduction of around 70% of
the striatal [11C]PE2I-BPND. However, pushing this value to more than
80% reduction compared to control induces stable parkinsonian symp-
toms that no longer permit spontaneous recovery. This is in agreement
with a large bodyof evidence suggesting that i) compensatory processes
involve multiple systems but nevertheless invariably engages the DA
pathway, and that ii) heterologous mechanisms are efﬁcient provided
about 20% of nigrostriatal projections remain functional.
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